利妥昔单抗治疗膜性肾病的有效性及对抗PLAR抗体的影响

打开文本图片集

[Abstract]Objective： To analyze the eficacy of Rituximab in the treatment of membranous nephropathy and its effect on anti-phospholipase A2 receptor （ PlA2R ）antibody.Method：The subjects of this studywere 92 patients with membranous nephropathy from January 2O23 to January 2025 in the Department of Nephrology， Ruikang Hospital Afiliated to Guangxi Universityof Chinese Medicine.Allpatients were randomlydivided into the control group and the observation group，46 cases in each group.The control group was treated with Cyclosporine combined with low-dose glucocorticoid， whilethe observation group was treated with Rituximab by intravenous drip， a complete course oftreatment lasted for 4 weeks，and both groups were treated for 3 courses continuously.The renal function，anti-PLA -2 Rantibody level and inflammatory indexes of the two groupswere compared before and after treatment.Result：After treatment，thelevels ofScr，24-hoururine proteinquantification，andblooduricacid （BUA） inthe observation group were lower than those in the control group，whilethe albumin （ALB）level was higher than that in the control group （ P <0.05）. After treatment，the anti-PLA R antibody level in the observation group was lower 12 than that in the control group （ P <0.05）. After treatment， the levels of inflammatory markers [hs-CRP，IL-6，and CXC chemokine ligand 13 （CXCL13）] in the observation group were lower than those in the control group （ P <0.05）. Conclusion： Rituximab treatment in patients with membranous nephropathy can effectively improve renal function， reduce the level of anti-PLA2R antibody and alleviate inflammatory reaction.

[Keywords] Rituximab Membranous nephropathy Anti-phospholipase A2 receptor Renal function

First-author'saddress：DepartmentofNephrology，RuikangHospitalAfiliated toGuangxi University of Chinese Medicine，Nanning53oooo，China doi：10.3969/j.issn.1674-4985.2026.07.023

膜性肾病以肾小球基底膜弥漫性增厚为特征性病理表现，若未及时干预，病情易进展为肾功能不全，显著降低患者生活质量并影响远期预后[-2]。（剩余6036字）